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ABSTRACT 
The evidence base supporting genetic and genomic sequence variant interpretations is 
continuously evolving. An inherent consequence is that a variant’s clinical significance might be 
reinterpreted over time as new evidence emerges regarding its pathogenicity or lack thereof. This 
raises ethical, legal and financial issues as to whether there is a responsibility to recontact 
research participants to provide updates on reinterpretations of variants after the initial analysis. 
There has been discussion concerning the extent of this obligation in the context of both research 
and clinical care. While clinical recommendations have begun to emerge, guidance is lacking on 
the responsibilities of researchers to inform participants of reinterpreted results. To respond, an 
American Society of Human Genetics (ASHG) workgroup developed this position statement, 
which was approved by the ASHG Board in November 2018. The workgroup included 
representatives from the National Society of Genetic Counsellors, the Canadian College of 
Medical Genetics and the Canadian Association of Genetic Counsellors. The final statement 
includes twelve position statements that were endorsed or supported by the following 
organizations: Genetic Alliance, European Society of Human Genetics, Canadian Association of 
Genetic Counsellors, American Association of Anthropological Genetics, Executive Committee 
of the American Association of Physical Anthropologists, Canadian College of Medical 
Genetics, Human Genetics Society of Australasia, and National Society of Genetic Counselors.
  
INTRODUCTION 
The American Society of Human Genetics (ASHG) workgroup developed this position statement 
with evidence-based justifications between January 2018 and November 2018. The workgroup is 
composed of a combination of laboratory and clinical scientists, laboratory directors, medical 
geneticists, primary care providers, bioethicists, health services researchers, lawyers, and genetic 
counsellors. The workgroup included representatives from the National Society of Genetic 
Counselors, the Canadian College of Medical Genetics and the Canadian Association of Genetic 
Counsellors. The workgroup has reviewed the literature in order to develop evidence-based 
recommendations with accompanied justifications, presented herein. Our analysis aligns with a 
previously published return of results consensus statement,1 expanding the discussion to 
recontact for return of updated results from reanalysed genetic data. 
 
The group met regularly through a series of bi-weekly conference calls and email discussions, 
proposed a draft outline of the statement to the ASHG Board of Directors in April 2018. A draft 
of this statement was reviewed by the ASHG Board of Directors on October 15, 2018. The 
Board requested revisions, which were reviewed by the committee and incorporated in the 
current statement. A consultation with the broader membership occurred during an invited 
session at the ASHG annual conference on October 19, 2018. There was a lively discussion and 
additional comments were invited via email. The Executive Committee of the Board reviewed 
and approved the current, revised statement on November 15, 2018. 
 
The final statement includes twelve position statements that were endorsed or supported by the 
following organizations: Genetic Alliance, European Society of Human Genetics, Canadian 
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Association of Genetic Counsellors, American Association of Anthropological Genetics, 
Executive Committee of the American Association of Physical Anthropologists, Canadian 
College of Medical Genetics, Human Genetics Society of Australasia, and National Society of 
Genetic Counselors. 
 
Currently research-related recontact typically happens on an ad hoc basis, which can lead to 
inequitable information provision and outcomes. Guidance is needed on how recontact should be 
operationalized in both clinical and research settings. This position statement addresses this 
critical policy gap in order to provide necessary guidance to our research communities. We 
recognize that not all research studies return results; these recommendations pertain to situations 
where the return of results has already occurred with the approval of the institution's IRB. These 
recommendations are intended to provide a set of principles; ultimately it is up to institutional 
review boards and advisory boards as to how these principles are operationalized.    
 
Our statement acknowledges that the responsibility to recontact a research participant could 
occur in some instances when a researcher finds evidence to support the reclassification of a 
variant according to professional standards.2  New knowledge might be learned about a variant 
that was previously returned to a study participant, or a medically relevant variant might be 
newly identified.  In either case, a strong responsibility is limited to situations in which there are 
adequate resources to support such recontact (e.g. the research project is ongoing and has active 
funding). ASHG acknowledges any participant’s right to decline return of results at the time of 
recontact. Further instances of recontact in this document imply that return is offered, not that 
return is made without participant agreement. Finally, the absence of an ASHG recommendation 
6 
 
to recontact in situations other than those enumerated below should not be interpreted as ASHG 
opposition to recontact in other situations. Rather, such omission indicates only that there is 
insufficient evidence available at this time for ASHG to issue a recommendation, and that in 
such situations the determination regarding recontact should be made on a case-by-case basis. 
 
SCIENTIFIC BACKGROUND  
The evidence base supporting genetic and genomic sequence variant interpretations is 
continuously evolving. An inherent consequence is that a variant’s clinical significance might be 
reinterpreted over time as new evidence emerges regarding its pathogenicity or lack thereof. This 
raises ethical, legal and financial issues as to whether there is a responsibility to recontact 
research participants to provide updates on reinterpretations of variants after the initial analysis. 
There has been discussion concerning the extent of this obligation in the context of both research 
and clinical care.3 While clinical guidance has begun to emerge,4,5 guidance is lacking on the 
responsibilities of researchers to inform participants of reinterpreted results.  
What does it mean to reinterpret results? 
Reinterpretation of genetic and genomic results might occur at multiple levels. Most frequently, 
there is reinterpretation of the implications of one or more validated sequence variants. This 
might occur as a revision of an interpretation of the significance of a previously analysed variant, 
changing the status among the common categories of Pathogenic (P), Likely Pathogenic (LP), 
Variant of Uncertain Significance (VUS), Likely Benign (LB) and Benign (B), effectively 
reclassifying the variant. Such reinterpretation might be the result of reanalysis within a given 
laboratory after observation in another individual, or might be based upon new or revised data 
published elsewhere about a particular variant or gene. Clinically, P and LP are generally treated 
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the same, and typically VUS are not acted upon.6 Thus, changes between P and LP may not have 
great consequence to participants, while changes from P/LP to VUS/LB/B or vice versa may.  
 
New interpretations might emerge from sequence data that had not previously been analysed. 
This could be due to the recognition of a gene or sequence of interest that was not previously 
known to be relevant, changes in lists of genes and sequences recommended for routine analysis 
(e.g. the ACMG secondary findings list4), or revisions of the scope and/or goals of a research 
project.  
 
Due to ongoing improvements in analytical methods and bioinformatic analyses, resequencing of 
an original specimen or reanalysis of raw sequence data might lead to a newly detected variant 
that was missed based on factors such as poor coverage or limitations in variant detection 
algorithms and filtration.7–17  
 
The above situations may or may not justify an effort on the part of the research team to 
recontact a participant to disclose new information. In addition, recontact might be considered 
appropriate if there is a change in a research project’s threshold of what types of variants should 
be disclosed at all, such that variants that were uniformly not disclosed in the past later meet 
criteria for disclosure after a participant had originally received his or her results. 
 
How often does reinterpretation occur? 
There is a relatively high rate of reclassification of variants, although the estimated rates vary 
across clinical indications for testing. In two early publications, Murray et al. (2011) found that 
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over half of BRCA1/BRCA2 VUS (60/107) were reclassified, the majority of these (39/60) 
downgraded to benign. Aronson et al. (2012) reported on 214 variant classification changes in 11 
hypertrophic cardiomyopathy genes over six years. The majority (56 variants) were upgraded 
from VUS to LP, 26 reclassified from LP to VUS, 32 from VUS to LB, another 25 variants 
changed between LB and B, and 62 changed between LP and P.  More recent reclassification 
reports in both clinical and research settings demonstrate that the majority of reclassifications are 
downgrades,18–21 largely due to the emergence of resources to document allele frequencies in 
diverse populations22 as well as more rigorous criteria for classifying pathogenic sequence 
variants.2 For example, Kast et al. (2018)18 found 18/40 VUS downgraded to LB/B.  
 
Importantly, a subset of cases of reclassifications can impact clinical management through 
screening, treatment or familial testing recommendations.20,21,23 For example, Turner et al 
(2018)20 reported that 12% of reclassifications (16/142) had the potential to alter clinical 
management: 6 of these were downgrades from P/LP to VUS (in BRCA1, BRCA2, TP53, and 
CHEK2) and 10 were upgrades from VUS to P/LP (in HNF1A, MSH6, BRCA1, SDHD, and 
PMS2). Because surgery is often considered at the time of diagnosis, in some cases individuals 
might have undergone unnecessary surgeries by the time reclassification occurs. Indeed, Murray 
et al. (2011)19 report on four women whose VUS was later reclassified to benign who underwent 
risk-reducing mastectomy or oophorectomy. In two cases, the documented main reason was 
"strong family history of breast cancer."   
 
These issues are further challenged by discordant (re)classification of variants and uncertainty of 
variant interpretations. Several studies have reported discrepancy rates in variant interpretation 
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between laboratories ranging from 39% to 66%.24–28 Bland et al. (2017)29 demonstrated that 
clinician experts’ classifications of variants differed from laboratories’ 18% of time, and 
differences were generally clinically significant. They found that clinicians tended to be more 
conservative in their classifications. Shah et al. (2018)30 analysed the dynamics of re-
classification of variant pathogenicity in ClinVar over time, which indicated progressive 
improvement in variant classification, favoring a general direction away from P/LPLB/B. 
However, the bulk of reclassified variants are reassigned to the “conflicting interpretation” 
category. More recent analyses have shown a more even distribution of upgrades and 
downgrades as laboratories continue to resolve discrepancies in variant classification.31,32 
Finally, reclassification rates also vary by ancestry/ethnicity,33 highlighting potential disparities 
in the rate of recontact among participant communities.  
Stakeholder perspectives 
With the exception of a few studies,18,33–35 the evidence base on stakeholder perspectives on 
recontact predominately originates from the clinical setting. Most of the literature focuses on 
patient and professional preferences, with some recent evidence emerging on the experience and 
feasibility of recontact (albeit in the clinical setting). Thus, there is a relative paucity of data on 
the most relevant population for the purpose of this statement.  
 
In the clinical setting, research addressing patients’ and research participants’ perspectives on 
recontact indicates that majorities of patients and participants surveyed (69-97%) across various 
disease groups felt that the physicians are responsible for recontacting patients about new 
developments that could improve their or their family’s care.35–38 One clinical study found that 
some patients favor a “joint venture” of recontact, where patients and healthcare providers share 
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the responsibility for recontact.39 However, patients appreciate the tension between the 
desirability of recontact and a perceived lack of feasibility.38 To this end, in at least some 
jurisdictions, patients have recommended that health professionals ask patients during their visits 
whether they want to be recontacted, and do so using personalized letters either annually or 
“when new discoveries are made”.35  
 
Fewer studies have assessed professionals’ perspectives on recontact. A 1999 survey of the 
ASHG membership found that the community was divided on whether recontacting clinical 
patients should be the ‘standard of care’.40  Interestingly, scientists were more likely to perceive 
a responsibility to recontact compared to clinicians (54% vs. 43%).40 A Canadian survey of 
researchers found that large majorities agreed that, in general and in a variety of hypothetical 
research contexts, research teams that report results should ensure that research participants gain 
subsequent access to updated information (74–83%).41 Carrieri et al. surveyed clinical genetics 
service providers in the UK and found that while the vast majority (95%) reported that they 
recontact patients and their family members, there are no standardized practices and the majority 
of services recontact on an occasional, not systematic, basis.42 Later the same authors 
interviewed 30 healthcare professionals and clinical laboratory scientists and found that recontact 
was a concern, with no standard practices and unclear lines of responsibility in the clinical 
context.38 These clinicians and clinical scientists acknowledged that recontact requires 
multidisciplinary collaboration, and that patients should sometimes take on some of the 
responsibility. Participants also expressed a need for consensus about recontact, and concerns 
about infrastructure and resources required.38  
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Recent evidence has begun to emerge about patients’ and research participants’ experiences with 
recontact. Taber et al. (2018)34 surveyed ClinSeq research participants who had been recontacted 
about new information pertaining to their Duarte galactosemia variant, which had been 
reclassified from pathogenic to benign. They found that research participants were able to 
understand variant reinterpretations of either a neutral change or a change from carrier to non-
carrier of a low risk condition, and that there were minimal adverse effects (though all 
participants were of high socioeconomic status). However, this change in classification would 
not have immediate impacts for these research participants’ health; there is a need for more 
research among research participants recontacted about changes with greater personal health 
impacts. Romero (2018)37 surveyed clinical adult patients who had been recontacted to inform 
them of new genetic tests related to their medullary thyroid carcinoma or pheochromocytoma/ 
paraganglioma. Only a minority of patients (29%, n=28) discussed genetic testing with their 
doctor or genetic counselor (9.5%), and 8.5% had genetic testing. Beunders et al. (2018)36 
surveyed parents of children who had received genetic testing for Fragile X syndrome or 
intellectual disability, who were recontacted and offered new tests (array CGH or whole exome 
sequencing) that might inform their child’s diagnosis, and for the most part parents reported 
positive experiences in the clinical setting (83% were pleased to be recontacted, n=47).  
 
Professionals’ experiences with recontacting offers another perspective. The 1999 ASHG survey 
of the ASHG membership indicated that while 61% of genetics professionals have recontacted 
patients or research participants in the past, only 13% had formal system in place to do so.40 This 
was consistent in a recent survey of 8 Canadian diagnostic labs, where none had a protocol for 
systematically reinterpreting previously analysed variants.43 A European survey of 105 genetics 
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centers demonstrated that 95% (100/105) of clinical centers have recontacted patients; of these, 
37 centers did so routinely, whereas 63 recontacted occasionally.44 Common reasons justifying 
recontact efforts ranged from: availability of a new test (n=55), new clinical guidance (n=33), 
reclassification of a VUS (n=26) to new results from prior test (n=17).44 Many European centers 
(41 of 105) have a formal system in place for recontacting patients, including: seeking consent at 
first visit, patients request or agree to future contact, or recontact occurs without prior consent 
(this was usually done when results are clinically actionable [n=44] or are medically relevant to a 
relative [n=16]).44 Interestingly, Beunders et al. (2018)36 compared the feasibility and yield from 
recontacting their patients by telephone versus letters. Total yield of parents who made 
appointments for re-evaluation was 36% of the 151 parents who were informed by telephone, 
and 4% of the 52 parents who were informed about recontact by letter. They also concluded that 
recontact was very time consuming, especially in selecting appropriate patients. 
 
Overall, the evidence indicates that most stakeholders, primarily representing the clinical setting, 
consider recontacting patients or research participants to be ethically desirable though practically 
difficult,45 and all point to a need for greater guidance on this issue. 
Current guidance on recontact 
Currently, guidelines addressing recontact are sparse and focus exclusively on the clinical 
context and not on the research setting. Only two clinical guidelines exist that explicitly address 
recontact: a 1999 position statement from the American College of Medical Genetics and 
Genomics (ACMG) and a recently published guideline from the European Society of Human 
Genetics (ESHG5). The 1999 ACMG guidelines suggest that recontact might be merited if new 
information is learned about a condition, but recommend that this be the responsibility of 
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primary care physicians who have more regular contact with patients than genetics specialists. 
The ACMG guidance also recommend that patients keep their primary care physician informed, 
or ask for updates about their results, suggesting a dual responsibility for recontacting. As of the 
writing of this statement, the ACMG was in the process of updating their guidelines. The ESHG 
recently recommended that clinicians should recontact patients regarding findings with clinical 
or established personal utility yet there is no legal or professional responsibility to do so.5 They 
add that recontacting is a shared responsibility with patients and laboratories, where requests for 
reanalysis should be initiated by the patient, clinical laboratory or their clinician.5  
 
Additional policy statements on other topics from the Canadian College of Medical Genetics 
(CCMG) and ACMG/American Association of Pediatrics (AAP) have briefly addressed clinical 
recontact, but it has not been the sole focus of any one recommendation. ESHG and EuroGentest 
previously concluded that clinical laboratories do not have a responsibility to routinely re-
analyse data, but that if a variant is reclassified the clinical laboratory should identify patients 
affected by the change and report this to their clinicians. 46,47 Whereas the CCMG state that re-
analysis should be initiated by the clinician.48 ACMG/AAP encourage recontact if a variant is 
reclassified, but leave it to the discretion of clinical laboratories to determine when to re-analyse 
and when to recontact.2 All statements point to a need for policies that specifically address when 
and how recontact should occur in the clinical setting. There is a paucity of guidance about 
recontacting in the research setting. 
 
14 
 
Scope of statement 
Recontact after reinterpretation of genetic and genomic research results is a complex issue in 
which both clinical and research laboratories, clinicians and researchers across specialities and 
research participants all have potential roles to play. Currently, research-related recontact 
typically happens on an ad hoc basis – this might cause inequitable information provision and 
outcomes. There is a need for guidance on how recontact should be operationalized, and when 
and how it should occur, especially in the research setting – a setting where no guidance 
currently exists.  
 
This position statement addresses this critical policy gap in order to provide necessary guidance 
to our research communities. It limits its recommendations to primarily research settings, while 
recognizing that genetic and genomic research results often impact clinical and other contexts. 
Indeed, even within a given research study or registry, there are varying degrees of crossover 
into the clinical realm (e.g. MyCode® Community Health Initiative at Geisinger). This statement 
attempts to address these research/clinical “grey zones” but recognizes that additional input from 
other stakeholders will be important as the experience with, and evidence base of, recontacting 
research participants grows. 
 
Exclusively clinical contexts are outside the scope of this position statement, given the existing 
guidance on the topic. The position statement also avoids discussions related to researchers’ 
obligations to recontact decedents when the proband/research participant is deceased, since this 
is the focus of separate guidance recommending that researchers have no obligation to return 
results to relatives (when proband is deceased) and no “duty to hunt” for such results.49 This 
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position statement also excludes the cases where initial consent was received while a participant 
was a minor and related discussion as to what happens when such individuals reach adulthood, 
since this is beyond the scope and intent of this statement.  
 
This document focuses exclusively on the recontact of study participants following the initial 
return of research results and does not address the issues relevant to initial return of a result.  In 
other words, should reinterpretation occur in the context of interpretation of a gene not 
previously analysed, or similar, then study protocols should be followed; this document instead 
focuses on the recontact of participants when a variant has already been returned and, 
subsequently, a reinterpretation of that variant is made. The ASHG endorses a prior consensus 
statement on the initial return of genomic results to research participants.1   
Ethical principles  
It is important to ground this guidance in an appropriate set of ethical principles because policies 
addressing these issues should strive to reflect the same principles applied across all types of 
research ethics questions. It is appropriate, then, to start with the principles proposed in the 
Belmont Report, the document that provided the ethical foundation for modern research 
regulations in the U.S.50 The Belmont Report suggests that three principles provide the 
foundation for ethically appropriate research with human participants: respect for persons, 
beneficence, and justice. Overlapping principles grounded in medical ethics commonly cited 
come from Beauchamp and Childress: beneficence, non-maleficence, respect for 
persons/autonomy, and justice.51  
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Among these three principles, respect for persons is potentially the most expansive. The framers 
of the Belmont Report interpreted this principle primarily from the perspective of autonomy: 
researchers are obligated to demonstrate respect for research participants by ensuring that 
participants have the opportunity to consider the risks and benefits of the research and 
voluntarily agree (via an informed consent process) to participate in the research. By 
emphasizing autonomy, this principle emphasizes that a broad range of approaches to returning 
genetic and genomic results revealed through reanalysis can potentially be ethically acceptable, 
assuming that this approach is made clear during the consent process to which the research 
participant has knowingly agreed. This is also, of course, why it is more difficult to deal with 
these issues when a plan has not been developed prospectively and included in the consent 
process. 
 
It is also important to recognize that the obligation for researchers to demonstrate respect for the 
participants could entail a number of other important ethical principles.52,53 Chief among these is 
the ethical principle of veracity or truth telling. In general terms, this aspect of the principle of 
respect for persons holds that researchers should not lie to participants unless there is scientific 
reason to do so (such as in psychological research that involves misdirection).54 The ethical 
principle of veracity supports a limited obligation to return reinterpreted results, as the 
communication of the original research results to a participant could be seen as information that 
is now known not to be true, thus creating a limited obligation to correct this. As always, this 
interpretation of veracity would need to be weighed along with a range of other ethical 
principles. 
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In the research context, the principle of beneficence functions slightly differently from the way it 
is applied to clinical care.55 In the clinical context, beneficence holds that healthcare providers 
have a fiduciary duty to pursue the best interests of their patients. In the research context, 
maximizing benefits and minimizing risks to research participants needs to be weighed against 
the overall aim of research: to generate new important scientific knowledge. It is necessary for 
researchers to carefully consider how to pursue scientific knowledge using an approach that 
confers the best possible balance of risks and benefits while still generating the benefits of high-
quality research. In other words, any responsibility that researchers have to provide benefits to 
their research participants (also known as an ancillary care responsibility) is necessarily a limited 
responsibility.56 
 
Justice, when applied to human research, can be operationalized in three ways in the context of 
the scientific value of research. First, researchers should be just in recruiting and enrolling 
participants in research studies. Except where justified by the scientific goal of the research, 
participants should have both equal access to the benefits of the research and equal exposure to 
its risks.57 Second, decisions about the funding of research also need to be guided by the 
principle of justice. Third, since the risks associated with human research are justified largely by 
the potential benefit of research to generate scientific knowledge and provide benefit to society 
at large, both researchers and funders might need to prioritize scientific aims over other aims. 
For example, imagine that a psychological study is being conducted in a primary care clinic to 
answer an important scientific question, but the study also provides a mechanism for patients to 
receive psychological treatment. If that psychological treatment ends up being more expensive 
than originally anticipated (i.e. because participants need more intensive therapy than expected), 
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then researchers might need to curtail this ancillary care in order to ensure that enough budget is 
available for the study to achieve its scientific aims. The principle of justice dictates that the 
scientific aims of a research study must be protected, or else the risks assumed by participants 
would not have been justified. 
 
These related aspects of beneficence and justice highlight the importance of practicability in 
applying ethical principles to the conduct of scientific research. There are a wide range of 
practices that researchers might want to adopt that would not be absolutely necessary for a 
research study to achieve its goals. For example, clinical study personnel sometimes send 
birthday cards or newsletters as a way to maintain participants’ engagement with a research 
study. Biorepositories sometimes choose to return individual research results to participants to 
help prevent participants from experiencing adverse health events. If it is possible to successfully 
carry out these practices, and to do so without threatening the overall ability of the study to 
achieve its scientific aims, then these practices can be said to be practicable - they are capable of 
being done while not threatening the goals specific to a research study, i.e. to generate scientific 
knowledge and provide societal benefits.1 
 
Practicability, then, provides a way to ethically weigh the potential conflicts that might arise in 
trying to balance ethical principles. The efforts of biorepositories to return individual research 
results to participants can be seen as a way to express respect for the contributions that 
participants have made to research.52 While this expression of respect can be seen as an ethical 
good, this good must be weighed against other ethical goods. As we have seen, the principle of 
justice could limit this particular expression of respect for persons if, in fact, an effort to return 
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individual research results would prevent the biorepository from achieving its scientific aims (i.e. 
because it costs too much or because it requires too much effort from research staff). 
In thinking about potential reasons that a researcher might need to return reinterpreted findings 
to participants, practicability provides a valuable framework for thinking about when this might 
or might not amount to an ethical obligation. Assuming that researchers utilize criteria that 
ensure the potential benefits of returning updated findings are maximized, taking on this 
additional effort would clearly provide an ethical good. However, whether there would be an 
ethical obligation to provide this good depends on a number of contextual factors. Practicability 
requires that the primary obligation of the researcher is to justify the risks that participants have 
assumed by ensuring that the research being conducted is completed successfully and is used to 
provide the scientific knowledge and societal benefit that it was designed to provide. Where this 
aim can be achieved while at the same time providing the service of reanalysis and return of 
updated results, making this effort clearly could provide additional benefit to research 
participants. However, where there are no resources at all to carry out this extra effort (e.g. after 
the funding for a research study has ended) or where it cannot be carried out without interfering 
with the study’s scientific aims (e.g. when it would consume grant funds that are required to 
complete the study), then a case could be made that it would be unethical or impossible to pursue 
the return of reinterpreted results. 
The use of practicability as a standard for deciding when there might be a responsibility to return 
reinterpreted results creates an obvious challenge: How should decisions be made about what is 
practicable? An important concern, of course, is that if the decision is left to researchers alone 
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the researcher might determine that an effort to return reinterpreted results is not practicable, 
when in fact it is practicable but inconvenient. From a pragmatic perspective, then, it is 
important that such decisions not be left solely to researchers. Typically, these types of 
evaluations are made by allowing researchers to present justification to the IRB, with the IRB 
making a final decision. However, other models of research governance are possible, and IRBs 
might approve plans to use advisory boards (such as groups of internal stakeholders or 
community advisory boards) to make these types of decisions. 
 
With all of this in mind, however, it is worth re-emphasizing that a broad range of approaches to 
returning updated results can be permissible. Assuming these plans are developed prospectively, 
these need to be evaluated by an IRB to ensure that the principles of respect for persons, 
beneficence, and justice are being respected to the extent possible, and then included in a 
thorough informed consent process so that participants have enough information to voluntarily 
agree to the plan. 
 
In summary, then, based on these ethical principles, the obligation to recontact is stronger when: 
a. The research is active, ongoing, has funding and participant’s contact information is up to 
date (practicability) 
b. Informed consent set the expectation for potential recontact (respect for 
persons/autonomy) 
c. There is a high degree of certainty about the new interpretation and/or implications of a 
changed interpretation, as judged by both investigator and IRB/governance structure 
("non-maleficence") 
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d. The reinterpretation would be relevant to the condition under study or, in the case of an 
actionable incidental finding, likely to change medical management (beneficence) 
Legal implications45,49,58,60,62,64,66,68–70,72,74,76,78,80,82,84,86,88,90  
It is also important to ground this guidance in an appropriate set of legal principles, the first of 
which is consideration of fiduciary relationships. Fiduciary relationships are ones in which a 
person in a position of greater power is under an obligation to act for the benefit of another 
within the scope of the relationship. In other words, the fiduciary is to have undivided loyalties 
to the beneficiary. Fiduciary relationships might rise from contractual agreement, and it is 
important to recognize that fiduciary duties do not arise simply by virtue of an imbalance of 
expertise. A fiduciary duty is based in trust and is highly contextual. Absent explicit legislative 
authority establishing affirmative duties on researchers, courts in the United States have 
generally been unwilling to find that a researcher has fiduciary duties to research participants 
unless the researcher is also the participants’ treating physician. While the physician-patient 
relationship has been described as a fiduciary one, this characterization has been framed 
distinctly from general tort duties related to fulfilling the standard of care. One rationale for 
maintaining a false dichotomy between care and research is based on the notion of conflicts of 
interest. A treating physician’s primary duty of loyalty is to the individual patient to ensure the 
improvement or maintenance of the health and wellbeing of that individual patient; however, a 
researcher’s primary duty of loyalty is to scientific enterprise itself and the production of 
generalizable knowledge rather than the provision of any direct benefit to an individual 
participant. Another basis for the dichotomy has been the now fading conceptualization of 
participation in research as a transactional activity (requiring informed discussion and consent 
only at the time of initial enrolment in the research) rather than a participatory one (with ongoing 
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communication and interaction as appropriate). Courts have been unwilling to extend fiduciary 
duties to researchers and have noted the countless questions such an extension would raise (e.g., 
how long such a fiduciary duty would last, whether the duties would persist beyond the 
participation in the research, and how to determine the scope of institutional duties that would 
arise vicariously).  
 
Researchers could have duties arising from other theories, including general negligence (that is, 
failing to perform responsibilities according to the prevailing professional standard). As norms 
for the profession shift to accommodate more equitable and participatory approaches to research, 
genetics researchers could be required to stay current with technologies and methods as well as 
to provide participants with updated disclosures related to information previously disclosed or 
after-acquired information. The prevailing professional standard for the conduct of genetics 
research is set, in part, by issuance of position statements and recommendations by professional 
organizations, such as the ASHG. The recommendations provided in the present statement are 
not intended to establish a legal duty, although courts might find these recommendations useful 
if called upon to establish, define, or otherwise delineate the scope of a responsibility to 
recontact research participants.  
 
In addition to agencies and oversight authorities that might establish and occasionally revise 
codes of conduct and set performance obligations that researchers owe to their participants, 
research institutions and research sponsors might also have their own policies that relate to a 
responsibility to recontact participants. The recommendations provided in the present statement 
are not intended to supersede other policies. Researchers should consult their attorney and 
23 
 
relevant administrators to reconcile any discrepancies between these recommendations and any 
and all applicable laws and policies for the situation.  
 
RECOMMENDATIONS 
What – Nature of results 
The responsibility to recontact a research participant could occur in some instances when a 
researcher finds evidence to support the reclassification of a variant according to professional 
standards.2  New knowledge might be learned about a variant that was previously returned to a 
study participant, or a medically relevant variant might be newly identified. In either case, a 
strong responsibility is limited to situations in which there are adequate resources to support such 
recontact (e.g. the research project is ongoing and has active funding). ASHG acknowledges any 
participant’s right to decline return of results at the time of recontact. Further instances of 
recontact in this document imply that return is offered, not that return is made without participant 
agreement. Finally, the absence of an ASHG recommendation to recontact in situations other 
than those enumerated below should not be interpreted as ASHG’s opposition to recontact in 
other situations. Rather, such omission indicates only that there is insufficient evidence available 
at this time for ASHG to issue a recommendation. In such situations, the determination regarding 
recontact should be made on a case-by-case basis. 
 
Given these considerations, the ASHG offers the following recommendations: 
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1. ASHG strongly recommends attempting to recontact participants to offer updated 
results if the reinterpretation is related to the phenotype under study or reasonably 
expected to affect a research participant’s medical management.    
  
2. If the reinterpretation is not expected to affect management, recontact is advised, 
rather than strongly recommended, for correction of the classification of variant 
previously reported to the participant whose pathogenicity classification has changed 
from or to Pathogenic/Likely Pathogenic.   
 
The strength of ASHG’s recommendations to recontact diminishes when the evidence for 
medical benefit is less definitive. Clinical criteria for ‘affecting medical management’ are 
defined elsewhere by the ACMG and could serve as a resource for researchers4,59: 
● Serious conditions  
● Highly penetrant 
● Effective intervention available (screening or treatment) 
● Risk/benefit profile of intervention is favorable 
● Strong knowledge base about condition overall 
 
All of the above applies to disclosure of both primary and additional,61 also called secondary or 
incidental, findings. For primary findings, related to the participant’s phenotype under study, 
changes of clinical consequence (P/LP to B/LB/VUS or from B/LB/VUS to P/LP) recontact is 
advised, even in the case where medical management of the individual being tested will not 
clearly change, for example in most patients with already diagnosed cardiomyopathy.  
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It is acknowledged that expectations and decisions about medical management are appropriately 
shared between health care providers and patients, and that there are situations in which 
expectations between patients and health care providers are not aligned. For purposes of 
recommendation #1, the determination of what is ‘reasonably expected to affect medical 
management’ is to be considered from the perspective of the researcher but should be informed 
by clinical guidelines and, when practical, consultation with clinicians. 
 
What – Threshold considerations  
In general, thresholds should be considered relative to what a research participant has been led to 
believe based on results that either have (or have not) been disclosed to them already63 and what 
was stated in the research consent if it was addressed.  
The rationale for recontacting participants is strongest when: 
● A participant has been notified of a LP/P variant, which is later downgraded to 
VUS/LB/B 
● Researchers have told a study participant that no detectable variants of clinical 
significance have been identified, and a LP/P variant that might impact medical 
management is subsequently identified, or reclassified from VUS/LB/B. 
● Researchers have implied that a study participant harbors no detectable variants of 
clinical significance because no results have been returned and a LP/P variant is 
subsequently identified that might impact medical management. 
 
Recontact is advised when VUS were returned and are reclassified as LP/P.  However, recontact 
in these situations falls short of a strong responsibility because: 
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● By definition, VUS are subject to revision based on changing evidence.  Research 
participants who have VUS returned to them as part of research are (ideally) encouraged 
to seek clinical follow-up testing and counselling in the future. 
● There is even less responsibility if reclassification of a VUS to LP/P is not believed to 
impact medical management.    
● Recontact for reinterpretations from B/LB to VUS should be made on a case by case 
basis when there is anticipated benefit.  
 
Researchers have no responsibility to hunt/scan genetic and genomic data or literature for 
changes in variant interpretation, or to identify new genetic causes of disease, if not part of the 
original study.1,65,67 To do so would be outside the scope of what a researcher owes a study 
participant and might detract from the primary goals of research.  This position is consistent with 
consensus that exists among clinical diagnostic laboratories, which also do not have a duty to 
hunt for variant reclassifications 46 and our endorsement of a prior consensus statement on return 
of genomic research results.1  However, evidence to support variant reclassification might arise 
as part of a researcher’s work (e.g. via functional studies, literature searching, or data sharing). 
Researchers are responsible for the validity of variant classification and are urged to critically 
evaluate the source of and evidence supporting each classification. 
 
Given these considerations, the ASHG offers the following recommendation concerning the 
responsibility to hunt: 
 3. ASHG recommends that there is no responsibility for researchers to hunt or scan 
genetic and genomic data or literature for changes in variant interpretation. 
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When – Temporal considerations  
Consistent with related guidelines,1 no return of results should be expected after the close of 
study funding.  
 
4. The ASHG recommends that any responsibility to recontact is limited to the duration 
of research funding. Recontact after the conclusion of funding may be desirable if 
sufficient resources exist.  
 
It is important to distinguish temporal issues that need to be considered prospectively when 
planning a study versus those for ongoing studies, where the question of recontact emerges after 
study initiation.  
 
For prospective studies researchers should plan to complete any recontact for interpretations of 
variants related to the phenotype under study and/or reasonably expected to affect a research 
participant’s medical management.  
 
For ongoing studies in which there is no existing plan for recontact, researchers are encouraged 
to consider whether any recontact related to reinterpretations of variants related to the phenotype 
under study and/or reasonably expected to affect a research participant’s medical management 
(as defined in sections “What – Nature of results” and “What – Threshold Considerations”) is 
indicated prior to the end of study funding. The need for clinical confirmation of a research result 
might influence the process of recontact but is not expected to influence the timing. Funding for 
recontact might be challenging when not planned in the budget of an ongoing study. However, as 
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reviewed in section “How often does reinterpretation occur?”, the proportion of cases with 
variants whose reclassification has both strong scientific evidence and implications for medical 
management is likely to be modest.20,21 In some cases, especially large-scale sequencing studies 
that choose to recontact for variants beyond those related to the phenotype under study and/or 
those reasonably expected to affect a research participant’s medical management, supplemental 
funding might be necessary. 
 
5. The ASHG recommends that no responsibility to recontact exists when the IRB 
protocol associated with the study closes or identifiers are stripped, rendering further 
recontact infeasible.  
 
When the study protocol to which the participant consented closes, and IRB oversight ceases, the 
researchers' responsibility for recontact ends. Should the study Principal Investigator change in 
an ongoing study (such as a longitudinal study), ultimate responsibility for recontact is 
transferred in the same way as for responsibility of other study functions. 
 
6. The ASHG recommends that, when there is a strong recommendation for 
recontact, the recontact should occur within 6 months of the reinterpretation. 
 
When the certainty of the reinterpretation, the gene/disease association, and/or the medical 
relevance is less definitive, a longer duration for recontact is reasonable or even desirable, so as 
to allow more time to establish more certainty. A longer duration is also reasonable when 
recontact is pursued for reasons related to personal utility rather than medical management 
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(where personal utility refers to non-clinical benefits endorsed by patients, such as [but not 
limited to] family/ reproductive planning, life preparation, empowerment and advanced 
knowledge92). Such delay should balance against the risk that study funding or other resources 
may not be sufficient to support recontact in the future. 
 
As previously established, there is no “duty to hunt” or duty to re-analyse unless otherwise 
specified in the research consent or protocol. Likewise, there is no predetermined time frame for 
a frequency of reanalysis. The timeframes relate to the time since discovery of new evidence 
during the course of research. An example would be a researcher reclassifying disease-specific 
variants per the 2015 ACMG/AMP criteria2 prior to publication and in the course of this process, 
realizes that some variants previously adjudicated and returned as LP/P are now classified as 
VUS/LB/B. 
 
How – Operational issues 
The ASHG offers the following recommendations concerning operationalizing the responsibility 
to recontact: 
 
7. ASHG recommends that instances of recontact be documented.   
8. ASHG recommends that any responsibility for recontact is limited to a “good faith 
effort” to reach the participant within the limits of existing constraints, including 
(but not limited to) financial and personnel resources, the existence of accurate 
contact information for the participant and willingness of the participant to accept 
recontact. 
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For variant reinterpretation related to the phenotype under study and/or reasonably expected to 
affect a research participant’s medical management and a high certainty of evidence supporting 
reclassification (as defined in section “What – Nature of results” and “What – Threshold 
Considerations”) it is reasonable for researchers to make this information available to 
participants through direct individual contact if consistent with the overall study return of results 
policy. For reinterpretations of variants unrelated to the phenotype under study and/or not 
expected to affect a research participant’s medical management where individual results had 
already been returned, a broad-based notification (such as a newsletter or generic mailing) to 
study participants will likely suffice. 
 
It is important to distinguish operational issues that need to be considered prospectively when 
planning a study versus those for ongoing studies, where the question of recontact emerges after 
study initiation.  
 
For prospective studies, as part of an overall return of results plan, researchers should anticipate 
the possibility of needing to recontact participants following reclassification of variants and 
design the study protocol accordingly. This includes developing a process for maintaining 
communication with participants as well as ensuring necessary funding and staffing. 
Considerations for recontact for updating genetic and genomic results are similar to operational 
issues of best practices for return of initial genetic and genomic study results.4 
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For ongoing studies that did not consider recontact in an initial return of results plan, but where 
variant reclassification has prompted consideration of recontact, initial policies for 
release/disclosure of original genetic findings should be followed to the extent possible 
following IRB / ethics approval as needed.  This includes decisions related to return of only 
clinically validated results vs. research results, actual form of recontact (mail, electronic, web-
based, etc.), security considerations, notification of relatives of deceased participants, 
documentation, etc. For instance, in some circumstances documentation of reclassification within 
a report addendum in the medical record is warranted if the initial return of results protocol 
included deposition of genetic results into the medical record, but not if initial return of results 
included a personalized results letter to the study participant. 
 
How - Issues of Consent 
Informed consent and recontact first requires taking note of the informed consent and basic 
return of individual research results. It is important to distinguish consent issues that need to be 
considered prospectively when planning a study versus those for ongoing studies, where the 
question of recontact emerges after study initiation.  
 
For prospective studies: 
 
9. ASHG recommends that research projects develop a plan not only for initial return 
of results, but also for return (or not) of reinterpretations of those results. As part of 
that plan, research participants should be alerted to the likelihood that interpretations 
of results may change over time and be given the opportunity to provide informed 
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consent regarding the plan for return of results, including initial and reinterpreted 
results.  
 
 
This position is consistent with numerous recommendations that have stated that researchers 
should anticipate the possibility of return of individual genetic research results.1,67,69,71,73 Fabsitz 
et al. (2010)71 state: “Researchers should consider prospectively whether their study has potential 
to yield individual research results of clinical importance and describe plans for return of results 
in consent forms and processes.” As such, researchers should either state in the consent 
document that the participant might be contacted in the future and offered a research result or ask 
the participant in the consent document whether or not he/she would want to be contacted in the 
future to learn about a research result. Jarvik et al. (2014)1 further expound on this saying “The 
consent process and form should address the possibility that there might be both research results 
related to the primary intent of the research and findings that are incidentally discovered in the 
course of research, and participants should be able to clearly opt in or out of receiving these 
types of results either at the time of initial consent or at a later point in the study when the 
specific types of results the participants might receive can be best defined. […] Ideally, the 
original consent form would include the possibility for, or an option of, future contact to offer 
results not anticipated at the time of consenting.” 
 
Limitations include the fact that technologies, and therefore responsibilities, are rapidly changing 
and many studies have consent forms developed (and signed) when the breath of findings and 
possibility for reinterpretations was poorly anticipated. Researchers should develop a plan for 
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recontacting research participants in the future and include it in the consent form, including an 
option to decline future recontact entirely.1,75 
 
For ongoing studies, the original research consent documents are relevant in defining what 
will/will not be analysed, re-analysed and disclosed to research participants in the present and in 
the future. Original research consent documents are also relevant in determining how to 
approach whether or not to recontact participants.1,67,69,71,73 A consent document that explicitly 
addresses the issue (either stating or requesting permission) is a different situation than a consent 
document that ignores the issue (i.e. not stating either way whether recontact may or may not 
occur).  
 
If the research consent documents address the issue of recontact, the situation is fairly clear-cut 
and recontact can be initiated. If participants agreed to have individual results returned, it implies 
recontact for the same type of results has also been agreed to by the participant. 
 
10. ASHG recommends that, if the participant consented to any return of results at the 
time of original research consent, then consent to recontact for the same type of results 
is implied and therefore appropriate subject to the other recommendations in this 
policy statement. 
 
If the research consent documents do not address the issue of recontact or of return of research 
results, then depending on the nature of the information, researchers can and should turn to 
research ethics consultation service (e.g. the Clinical Research Ethics Consultation Collaborative 
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[RECs]) and/or IRB for guidance.71,77,79,81 In addition, a formal determination will likely need to 
be made through a conversation between the researcher and the local IRB. This discussion must 
take into account the specific details of each case in question. 
 
Of note, some institutions might have a local policy requiring return of any research finding 
(regardless of whether it is the initial return or a recontact to return reclassified results) to be 
approved by the IRB, even if it was stated in the protocol these might happen. That is, the local 
IRB might want to see the list of variants being returned (initially or as part of a recontact to 
return reclassified results) and justification for their return. 
 
Participants may change their minds regarding return of results overtime. In situations where 
researchers feel a strong desire to overrule participants’ initial consent to return initial results in 
order to recontact participants with reinterpreted variants, researchers should seek RECs 
guidance. 
Who - Professional roles  
Ideally, recontact protocols should be part of the initial research study design, with consideration 
for protocols that take into account the context and limitations of specific jurisdictions, in 
consultation with the IRB approving the study.  In cases where no protocol or procedure for 
recontact was previously put in place, and recontact is warranted according to the specifications 
outlined earlier in this document, the points below should be considered. When in doubt, 
consultation should occur with the IRB under which the research study was approved. 
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The ASHG offers the following recommendation to operationalize the responsibility to 
recontact: 
 
11. ASHG recommends that, ideally, the same individuals and communication methods 
should be used for recontact as were used for the initial return of results.  
 
Since recontact implies that an initial contact took place, ideally the same channels should be 
used for recontact as for the initial contact for the type of result. For example, a research protocol 
can suggest that negative and uncertain results are returned by letter, whereas detection of the 
P/LP variants or medically actionable incidental findings are returned by telephone or personal 
meeting. Ideally, the same individuals involved in the prior contact should be involved with 
recontact. If the individuals initially involved left the institution, then ideally the individual(s) 
who assumed their professional role will carry out the recontact. In cases where no designated 
individual assumed this professional role, another member of the same team with similar 
credentials would be the preferred individual to carry on the recontact. If none of these options is 
available, the research team should notify research participants according to the mechanisms 
outlined earlier in this document. If a clinician was initially involved in referring a patient-
participant to the study and/or managing study results, the research team should alert him/her to 
the new results. 
 
It is recognized that participant clinical access might be limited by funding considerations and/or 
limited specialized human resources. As such, while the information might be made available to 
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clinicians, clinicians should act according to the clinical guidelines/protocols that apply in the 
jurisdiction. 
 
There is a paucity of literature on duality of roles (clinician researchers) with the exception that 
perceived or real conflicts of interests should always be considered in the context of recontact, 
and a result conveyed by a healthcare provider who is actively treating the patient/participant is 
less likely to be perceived as value neutral by the participant, even if that provider is acting as a 
researcher at the time of conveying that result. A therapeutic intention is often assumed in such 
situations, even when patients are told otherwise.1,83,85 
 
As noted above, the absence of an ASHG recommendation to recontact in situations other than 
those enumerated above should not be interpreted as ASHG opposition to recontact in other 
situations. Rather, such omission indicates only that there is insufficient evidence available at 
this time for ASHG to issue a recommendation.  In such situations, the determination regarding 
recontact should be made on a case-by-case basis. However, as noted elsewhere1, “researchers 
might be ethically and scientifically justified in returning all genomic information.” If they are 
returning broader classes of information, they may be justified in recontacting for broader types 
of reinterpreted results.  
 
12. ASHG acknowledges that in the research context, participants may be consented for 
initial return of a much wider range of results. Thus, reinterpretations derived from 
reanalysis broader than those addressed in this statement are appropriate to return 
when that is consistent with study design and consent documents.  
37 
 
 
DISCUSSION 
It is now well-recognized that researchers should anticipate situations in which return of study 
findings might become appropriate.1,4,49,87 With recent data documenting the relatively high rate 
of reclassification of variants, researchers planning a study should likewise anticipate and plan 
for recontacting study participants during the life of their funded studies. Herein, the ASHG sets 
the minimum principles underpinning researchers’ responsibilities to recontact their research 
participants about variant reclassifications. 
 
A common theme in most critical evaluations of recontact is the inherent tension between the 
desire to keep research participants as informed as possible and the opportunity costs and 
practical challenges of actually accomplishing that goal. Depending upon the details of a given 
situation, the degree of ethical imperative for recontact and the associated obstacles might vary. 
There are different types of utility as well as potential harm, some of which are clearly medically 
actionable with quantitatively measurable effects on morbidity and mortality, while others are 
more personal, intangible and qualitative. The resource costs of recontact depend on multiple 
factors, including accessibility of the intended recipient of the recontact, the experience of the 
clinical/researcher, and the nature of the revised interpretation. Funding for those resource costs 
might be uncertain, especially after a study has closed, and any budget devoted to recontact 
necessarily represents resources that were not dedicated to some other purpose. 
 
These recommendations have been developed amidst an evolving landscape of related policies 
and guidance documents. For example, the recent report issued by the National Academy of 
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Sciences (titled, “Returning Individual Research Results to Participants: Guidance for a New 
Research Paradigm89”) included an entire chapter devoted to the issue of “reshaping” the legal 
landscape to make it more conducive to the return of individualized research results (see Chapter 
6). While NASEM concluded that there was not yet legal consensus on whether there is a right to 
access individualized research results and highlighted some regulatory challenges for doing so 
(such as perceived regulatory conflicts between HIPAA’s right to access and CLIA-certification 
requirements wherein some, but notably not all legal experts, interpret a non-CLIA-certified 
laboratory’s provision of access to individual research results in effort to comply with the civil 
right to access under HIPAA would necessitate the laboratory becoming CLIA-certified), 
NASEM underscored ethical and practical reasons for providing such access to individual 
research participants and advocated for harmonization and clarification of regulatory authorities 
(including OCR, CMS, and FDA). NASEM noted among the many liability concerns is the 
potential tort liability that might arise from a “[f]ailure to update previously disclosed results and 
to return the updated results.” Liability concerns, NASEM notably concluded, could be 
alleviated through the issuance of standards for reporting individual research results. Among the 
areas in which clarity could emerge (see NASEM Table 6-3) is if there would be a more specific 
articulation of what individual research data is (or should be) considered as belonging to the 
HIPAA designated record set (DRS) for mandatory disclosure.  
 
These recommendations could also be informed and updated in light of some much needed 
evidence. For example, data concerning the benefits, risks, costs, procedures and outcomes of 
recontacting participants about reinterpreted variants is limited as is researchers’ experiences 
with return of results and being recontacted about reinterpreted results. Reanalysing variant calls 
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and recontacting requires resources and funding, both of which are limited, or even non-existent, 
in ongoing studies. Dedicated funding is required to supplement researchers’ budgets to 
recontact participants, through institutional mechanisms or built in as part of future grant 
proposals. We urge funding agencies to encourage and financially support researchers’ efforts to 
recontact participants in light of re-classified variants.  
Enhancements in information technology (IT) will likely further reduce the opportunity costs of 
recontact, and open up new avenues of keeping patients and research participants informed. Most 
electronic medical record systems and many clinical laboratories now offer portals through 
which patients might see their data, interact with clinical, laboratory, and support staff, and 
access educational material. Databases can be interfaced and cross-referenced, enabling more of 
a self-service model of education. Some patients and participants are already being provided 
with some or all of their raw genetic test result data, in addition to the interpretation of that data. 
As our IT resources and our databases continue to evolve, it is plausible that much of the effort 
of recontact could become automated. When a variant is reclassified, an automated notification 
could be sent to all patients and subjects known to harbor that variant, alerting them of the 
revised interpretation and prompting them to log into the portal to view the new information and 
associated education. This future vision depends upon well-developed and interoperable 
databases, including both the interpretations of the variants and the lists of who has each variant. 
Effort will be required to identify which databases to include (or exclude), as well as how to 
manage conflicting data. Some laboratories have proposed databases or information technology 
approaches to recontact, some of which is used to track variant and patient data, and 
reclassifications, and could send updated reports directly to patients’ electronic medical 
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records.63,91 Potentially difficult questions about identity and privacy will need to be answered. 
There are also significant concerns about the “digital divide” and economic disparities; 
increasing reliance on IT solutions has the potential to discriminate against people who are 
unable to or choose not to utilize such resources. There will always be situations that require 
more nuance and explanation than an automated algorithm can achieve. But there is hope that IT 
enhancements can significantly lower the costs and barriers to recontacting research participants 
when it is considered desirable to do so. 
CONCLUSION 
Recontact after reinterpretation of genetic and genomic research results is a complex issue in 
which both clinical and research laboratories, clinicians and researchers across specialities and 
research participants all have potential roles to play. Currently, research-related recontact 
typically happens on an ad hoc basis, which can lead to inequitable information provision and 
outcomes. Guidance is needed on how recontact should be operationalized, and when and how it 
should occur, especially in the research setting – a setting where no guidance currently exists. 
This position statement addresses this critical policy gap in order to provide necessary guidance 
to our research communities. These recommendations are intended to provide a set of principles; 
ultimately it is up to institutional review boards and advisory boards as to how these principles 
are operationalized.  
  
These recommendations have been developed amidst an evolving landscape of related policies 
and might need to be updated in light of the paucity of evidence on the burden and outcomes of 
recontacting research participants. Future research and changes in both IT and social values will 
likely impact our society’s approach to applying ethical principles in conducting research and 
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keeping research participants as informed as possible about their genetic test results, even as our 
understanding of those test results evolves over time. Development of the evidence base along 
with ongoing stakeholder consultation is thus warranted to ensure the equitable and effective 
delivery of high quality research results to those who participate in research.  
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FIGURE TITLES & LEGENDS 
Figure 1:  Recommended pathway for considering recontacting participants after 
reinterpretation of genetic and genomic research results  
 [To be used in conjunction with recommendations listed in Box 1] 
 
Figure 1 Legend: Reinterpretation refers to both reclassification of variants and reanalysis 
of original data (per section “what does it mean to reinterpret results?”) 
 
Box 1:  Recommendations for recontacting participants after reinterpretation of genetic 
and genomic research results 
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Box 1:  Recommendations for recontacting participants after reinterpretation of genetic 
and genomic research results 
 
1. ASHG strongly recommends attempting to recontact participants to offer updated results if 
the reinterpretation is related to the phenotype under study or reasonably expected to affect a 
research participant’s medical management.   
2. If the reinterpretation is not expected to affect management, recontact is advised, rather 
than strongly recommended, for correction of the classification of variants previously reported 
to the participant whose pathogenicity classification has changed from or to 
Pathogenic/Likely Pathogenic.  
3. ASHG strongly recommends that there is no responsibility for researchers to hunt or scan 
genetic and genomic data or literature for changes in variant interpretation. 
4. ASHG recommends that any responsibility to recontact is limited to the duration of 
research funding. Recontact after the conclusion of funding may be desirable if sufficient 
resources exist.  
5. ASHG recommends that no responsibility to recontact exists when the IRB protocol 
associated with the study closes or identifiers are stripped, rendering further recontact 
infeasible.  
6. ASHG recommends that, when there is a strong recommendation for recontact, the 
recontact should occur within 6 months of the reinterpretation.  
7. ASHG recommends that attempts at recontact be documented.  
8. ASHG recommends that any responsibility for recontact is limited to a “good faith effort” 
to reach the participant within the limits of existing constraints, including (but not limited to) 
60 
 
financial and personnel resources, the existence of accurate contact information for the 
participant and willingness of the participant to accept recontact. 
9. ASHG recommends that research projects develop a plan not only for initial return of 
results, but also for return (or not) of reinterpretations of those results. As part of that plan, 
research participants should be alerted to the likelihood that interpretations of results may 
change over time and be given the opportunity to provide informed consent regarding the plan 
for return of results, including initial and reinterpreted results.  
10. ASHG recommends that, if the participant consented to any return of results at the time of 
original research consent, then consent to recontact for the same type of results is implied and 
therefore appropriate subject to the other recommendations in this policy statement.   
11. ASHG recommends that, ideally, the same individuals and communication methods 
should be used for recontact as were used for the initial return of results.  
12. ASHG acknowledges that in the research context, participants may be consented for initial 
return of a much wider range of results. Thus, reinterpretations derived from reanalysis 
broader than those addressed in this statement are appropriate to return when that is consistent 
with study design and consent documents.  
 
 
 
